Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus albumin-bound paclitaxel as neoadjuvant therapy for muscle-invasive bladder cancer
ChiCTR2000040487Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Jul 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and paclitaxel in transitional cell carcinoma (TCC) and bladder cancer, sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: pathologic complete response. Started Jul 2020; status: recruiting.
02
Drugs
tislelizumabpaclitaxel
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on ChiCTR2000040487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040487.